Cargando…

The prognostic and predictive value of mismatch repair status in patients with locally advanced rectal cancer following neoadjuvant therapy

BACKGROUND: We examined the predictive value of mismatch repair (MMR) status in relation to responses to neoadjuvant therapy and the prognosis of locally advanced rectal cancer patients. METHODS: A total of 854 consecutive patients with locally advanced rectal cancer with MMR status who underwent ne...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Zehua, Hu, Huabin, Wang, Chao, Zhang, Jianwei, Cai, Yue, Xie, Xiaoyu, Huang, Yan, Deng, Yanhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096371/ https://www.ncbi.nlm.nih.gov/pubmed/35571401 http://dx.doi.org/10.21037/atm-22-124

Ejemplares similares

Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair
por: Hu, Huabin, et al.
Publicado: (2020)

Prognostic impact of high-risk factors and KRAS mutation in patients with stage II deficient mismatch repair colon cancer: a retrospective cohort study
por: Zhang, Yuting, et al.
Publicado: (2022)

Association of mismatch repair status with survival and response to neoadjuvant chemo(radio)therapy in rectal cancer
por: Ye, Shu-Biao, et al.
Publicado: (2020)

Reduction of circulating lymphocyte count is a predictor of good tumor response after neoadjuvant treatment for rectal cancer
por: Wu, Zehua, et al.
Publicado: (2018)

Complete response in patients with locally advanced rectal cancer after neoadjuvant treatment with nivolumab
por: Zhang, Jianwei, et al.
Publicado: (2019)

Survival outcomes analysis according to mismatch repair status in locally advanced rectal cancer patients treated with neoadjuvant chemoradiotherapy
por: Chen, Lin, et al.
Publicado: (2022)

Distinct Clinicopathological Features and Prognostic Values of High-, Low-, or Non-Expressing HER2 Status in Colorectal Cancer
por: Wu, Zehua, et al.
Publicado: (2023)

Neoadjuvant versus adjuvant imatinib in primary localized gastrointestinal stromal tumor
por: Ling, Jiayu, et al.
Publicado: (2023)

Nomogram basing pre-treatment parameters predicting early response for locally advanced rectal cancer with neoadjuvant chemotherapy alone: a subgroup efficacy analysis of FOWARC study
por: Zhang, Jianwei, et al.
Publicado: (2015)

Neoadjuvant PD-1 blockade: a promising nonoperative strategy for mismatch repair–deficient, locally advanced rectal cancer
por: Mi, Mi, et al.
Publicado: (2022)

Cytokeratin 7 Expression and Mismatch Repair Status for Survival Prediction in Patients With Low Rectal Cancer After Neoadjuvant Therapy
por: Shi, Songli, et al.
Publicado: (2023)

Poor prognostic and staging value of tumor deposit in locally advanced rectal cancer with neoadjuvant chemoradiotherapy
por: Wang, Yaqi, et al.
Publicado: (2019)

Prognostic Value of the FOXK Family Expression in Patients with Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiotherapy
por: Zhang, Yiyi, et al.
Publicado: (2020)

Prognostic Value of the Distribution of Lymph Node Metastasis in Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiotherapy
por: Chen, Bin, et al.
Publicado: (2021)

Systemic neutrophil lymphocyte ratio and mismatch repair status in colorectal cancer patients: correlation and prognostic value
por: He, Wen-Zhuo, et al.
Publicado: (2018)

Prognostic and predictive value of extended RAS mutation and mismatch repair status in stage III colorectal cancer
por: Sasaki, Yusuke, et al.
Publicado: (2016)

Mismatch repair deficiency in rectal cancer: an evolving scenario
por: Longo, Federico, et al.
Publicado: (2022)

Gene Expression Signature to Predict Prognosis and Adjuvant Chemosensitivity of Colorectal Cancer Patients
por: Li, Jianxia, et al.
Publicado: (2020)

GRP78 Protein Expression as Prognostic Values in Neoadjuvant Chemoradiotherapy and Laparoscopic Surgery for Locally Advanced Rectal Cancer
por: Lee, Hee Yeon, et al.
Publicado: (2015)

Prognostic value of pretreatment systemic inflammatory markers in patients with locally advanced rectal cancer following neoadjuvant chemoradiotherapy
por: Zhang, Yiyi, et al.
Publicado: (2020)

Formation of Polyploid Giant Cancer Cells Involves in the Prognostic Value of Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer
por: Fei, Fei, et al.
Publicado: (2019)

Clinical significance of neoadjuvant chemotherapy for locally advanced colorectal cancer patients with deficient mismatch repair: possibly residual value in the era of immunotherapy
por: Chen, Mian, et al.
Publicado: (2023)

The efficiency of neoadjuvant chemotherapy in colon cancer with mismatch repair deficiency
por: Yunlong, Wu, et al.
Publicado: (2022)

Prognostic value of the micronucleus assay for clinical endpoints in neoadjuvant radiochemotherapy for rectal cancer
por: Dröge, Leif Hendrik, et al.
Publicado: (2021)

Pediatric Rectal Adenocarcinoma With Mismatch Repair Deficiency Responds to Immunotherapy
por: Qureshi, Naveen, et al.
Publicado: (2023)

Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2023)

CEA clearance pattern as a predictor of tumor response to neoadjuvant treatment in rectal cancer: a post-hoc analysis of FOWARC trial
por: Hu, Huabin, et al.
Publicado: (2018)

The value of diffusion kurtosis imaging in assessing mismatch repair gene expression of rectal carcinoma: Preliminary findings
por: Feng, Qiang, et al.
Publicado: (2019)

Prognostic Value of Interval Between the Initiation of Neoadjuvant Treatment to Surgery for Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemotherapy, Radiotherapy and Definitive Surgery
por: Wan, Xiang-Bo, et al.
Publicado: (2020)

Clinical influence of neoadjuvant chemoradiotherapy on immunonutritional status in locally advanced rectal cancer
por: Lee, Soohyeon, et al.
Publicado: (2023)

Neoadjuvant Chemoradiotherapy Changes the Landscape of Soluble Immune Checkpoint Molecules in Patients With Locally Advanced Rectal Cancer
por: Liu, Chao, et al.
Publicado: (2022)

Prognostic Value of Mismatch Repair Genes for Patients With Colorectal Cancer: Meta-Analysis
por: Hou, Jiang-tao, et al.
Publicado: (2018)

Prognostic and Predictive Values of Mismatch Repair Deficiency in Non-Metastatic Colorectal Cancer
por: Jin, Zhaohui, et al.
Publicado: (2021)

Controversies and management of deficient mismatch repair gastrointestinal cancers in the neoadjuvant setting
por: Boutin, Mélina, et al.
Publicado: (2023)

Prognostic and staging value of tumor deposits in patients with rectal cancer after neoadjuvant chemoradiotherapy
por: Xu, Tianlei, et al.
Publicado: (2021)

A Patient With Locally Advanced Mismatch-Repair-Deficient Pancreatic Ductal Adenocarcinoma Successfully Treated With Neoadjuvant Immunotherapy
por: Cox, Ronald E, et al.
Publicado: (2021)

Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer
por: Papaccio, Federica, et al.
Publicado: (2020)

Neoadjuvant Treatment in Rectal Cancer: Actual Status
por: Garajová, Ingrid, et al.
Publicado: (2011)

CT-based deep learning model for the prediction of DNA mismatch repair deficient colorectal cancer: a diagnostic study
por: Cao, Wuteng, et al.
Publicado: (2023)

Prognostic value of mesorectal package area in patients with locally advanced rectal cancer following neoadjuvant chemoradiotherapy: A retrospective cohort study
por: Guan, Bingjie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rlcgs9ai88k7vo2rjuav6og3kl